These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23817717)

  • 21. [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].
    Vaisbich MH; Henriques Ldos S; Watanabe A; Pereira LM; Metran CC; Malheiros DA; Modanez F; Silva JD; Vieira S; Macedo AC; Massarope B; Furusawa EA; Schvartsman BG
    J Bras Nefrol; 2013; 35(3):237-41. PubMed ID: 24100744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Eculizumab for atypical hemolytic uremic syndrome in newborn: a case report].
    Alonso-Triana YM; Perrino MJ
    Farm Hosp; 2015 Jul; 39(4):217-8. PubMed ID: 26276740
    [No Abstract]   [Full Text] [Related]  

  • 23. Eculizumab for atypical hemolytic-uremic syndrome.
    Nürnberger J; Philipp T; Witzke O; Opazo Saez A; Vester U; Baba HA; Kribben A; Zimmerhackl LB; Janecke AR; Nagel M; Kirschfink M
    N Engl J Med; 2009 Jan; 360(5):542-4. PubMed ID: 19179328
    [No Abstract]   [Full Text] [Related]  

  • 24. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.
    Giordano M; Castellano G; Messina G; Divella C; Bellantuono R; Puteo F; Colella V; Depalo T; Gesualdo L
    Pediatrics; 2012 Nov; 130(5):e1385-8. PubMed ID: 23027168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eculizumab therapy.
    Cataland SR
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
    [No Abstract]   [Full Text] [Related]  

  • 26. The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment.
    van den Heuvel LP; van de Kar NCAJ; Duineveld C; Sarlea A; van der Velden TJAM; Liebrand WTB; van Kraaij S; Schjalm C; Bouwmeester R; Wetzels JFM; Mollnes TE; Volokhina EB
    Cell Mol Immunol; 2020 Jun; 17(6):653-655. PubMed ID: 32210393
    [No Abstract]   [Full Text] [Related]  

  • 27. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.
    Larrea CF; Cofan F; Oppenheimer F; Campistol JM; Escolar G; Lozano M
    Transplantation; 2010 Apr; 89(7):903-4. PubMed ID: 20386298
    [No Abstract]   [Full Text] [Related]  

  • 29. More on eculizumab for congenital atypical hemolytic-uremic syndrome.
    Shin JI; Lee JS
    N Engl J Med; 2009 May; 360(20):2142-3; author reply 2143. PubMed ID: 19439754
    [No Abstract]   [Full Text] [Related]  

  • 30. Eculizumab for congenital atypical hemolytic-uremic syndrome.
    Gruppo RA; Rother RP
    N Engl J Med; 2009 Jan; 360(5):544-6. PubMed ID: 19179329
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.
    Prescott HC; Wu HM; Cataland SR; Baiocchi RA
    Am J Hematol; 2010 Dec; 85(12):976-7. PubMed ID: 20941783
    [No Abstract]   [Full Text] [Related]  

  • 33. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
    Châtelet V; Lobbedez T; Frémeaux-Bacchi V; Ficheux M; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2010 Dec; 42(10):4353-5. PubMed ID: 21168697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The alternative pathway of complement and the thrombotic microangiopathies.
    Teoh CW; Riedl M; Licht C
    Transfus Apher Sci; 2016 Apr; 54(2):220-31. PubMed ID: 27160864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postpartum hemolytic-uremic syndrome. How poor is the prognosis?
    Chester AC; Preuss HG
    Nephron; 1982; 32(1):95. PubMed ID: 6891028
    [No Abstract]   [Full Text] [Related]  

  • 36. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.
    Ariceta G; Arrizabalaga B; Aguirre M; Morteruel E; Lopez-Trascasa M
    Am J Kidney Dis; 2012 May; 59(5):707-10. PubMed ID: 22196848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 38. Early initiation of eculizumab therapy for Streptococcus pneumoniae-associated hemolytic uremic syndrome.
    See J; Bou Matar R; Baloglu O; Latifi SQ; Talati R; Agarwal HS
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28589. PubMed ID: 32672848
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.
    Wilson CH; Brown AL; White SA; Goodship TH; Sheerin NS; Manas DM
    Transplantation; 2011 Oct; 92(8):e42-3. PubMed ID: 21989273
    [No Abstract]   [Full Text] [Related]  

  • 40. Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.
    Reuter S; Heitplatz B; Pavenstädt H; Suwelack B
    Transplantation; 2013 Nov; 96(10):e74-6. PubMed ID: 24247905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.